IT1243390B - Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. - Google Patents

Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Info

Publication number
IT1243390B
IT1243390B IT02215590A IT2215590A IT1243390B IT 1243390 B IT1243390 B IT 1243390B IT 02215590 A IT02215590 A IT 02215590A IT 2215590 A IT2215590 A IT 2215590A IT 1243390 B IT1243390 B IT 1243390B
Authority
IT
Italy
Prior art keywords
controlled release
pharmaceutical compositions
pharmacologically active
procedure
preparation
Prior art date
Application number
IT02215590A
Other languages
English (en)
Other versions
IT9022155A0 (it
IT9022155A1 (it
Inventor
Tiziana Canal
Mara Lucia Lovrecich
Fabio Carli
Original Assignee
Vectorpharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma Int filed Critical Vectorpharma Int
Publication of IT9022155A0 publication Critical patent/IT9022155A0/it
Priority to IT02215590A priority Critical patent/IT1243390B/it
Priority to AT91119505T priority patent/ATE141788T1/de
Priority to ES91119505T priority patent/ES2094781T3/es
Priority to EP91119505A priority patent/EP0486959B1/en
Priority to DE69121675T priority patent/DE69121675T2/de
Priority to JP33273591A priority patent/JP3293862B2/ja
Publication of IT9022155A1 publication Critical patent/IT9022155A1/it
Priority to US08/139,051 priority patent/US5536508A/en
Application granted granted Critical
Publication of IT1243390B publication Critical patent/IT1243390B/it
Priority to US08/641,039 priority patent/US5700486A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT02215590A 1990-11-22 1990-11-22 Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. IT1243390B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT02215590A IT1243390B (it) 1990-11-22 1990-11-22 Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE69121675T DE69121675T2 (de) 1990-11-22 1991-11-15 Mikrosphäre enthaltende pharmazeutische Zusammensetzung mit kontrollierter Freigabe und Verfahren zur Herstellung
ES91119505T ES2094781T3 (es) 1990-11-22 1991-11-15 Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
EP91119505A EP0486959B1 (en) 1990-11-22 1991-11-15 Pharmaceutical composition of microparticles with controlled release and process of preparing it
AT91119505T ATE141788T1 (de) 1990-11-22 1991-11-15 Mikrosphäre enthaltende pharmazeutische zusammensetzung mit kontrollierter freigabe und verfahren zur herstellung
JP33273591A JP3293862B2 (ja) 1990-11-22 1991-11-22 薬物学的活性物質の調節的放出のために適した粒状医薬組成物及び上記組成物の製法
US08/139,051 US5536508A (en) 1990-11-22 1993-10-21 Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions
US08/641,039 US5700486A (en) 1990-11-22 1996-04-30 Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02215590A IT1243390B (it) 1990-11-22 1990-11-22 Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Publications (3)

Publication Number Publication Date
IT9022155A0 IT9022155A0 (it) 1990-11-22
IT9022155A1 IT9022155A1 (it) 1992-05-23
IT1243390B true IT1243390B (it) 1994-06-10

Family

ID=11192325

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02215590A IT1243390B (it) 1990-11-22 1990-11-22 Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Country Status (7)

Country Link
US (2) US5536508A (it)
EP (1) EP0486959B1 (it)
JP (1) JP3293862B2 (it)
AT (1) ATE141788T1 (it)
DE (1) DE69121675T2 (it)
ES (1) ES2094781T3 (it)
IT (1) IT1243390B (it)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH681425A5 (it) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
DE4120760A1 (de) * 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
RU2128055C1 (ru) * 1992-12-07 1999-03-27 Такеда Кемикал Индастриз Лтд. Фармацевтическая композиция замедленного высвобождения и способ ее получения
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
DE69529054T2 (de) * 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
GB2303551B (en) * 1994-06-18 1998-04-22 Univ Nottingham Polymer microparticles for drug delivery
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
AUPM855194A0 (en) * 1994-10-04 1994-10-27 Csl Limited Controlled-release pharmaceutical preparations
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
FR2755856B1 (fr) * 1996-11-21 1999-01-29 Merck Clevenot Laboratoires Microcapsules de chitine ou de derives de chitine contenant une substance hydrophobe, notamment un filtre solaire et procede de preparation de telles microcapsules
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6350322B1 (en) * 1997-03-21 2002-02-26 Micron Technology, Inc. Method of reducing water spotting and oxide growth on a semiconductor structure
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US7025991B2 (en) * 1997-06-13 2006-04-11 Nanodel Technologies Gmbh Drug targeting system, method of its preparation and its use
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
CA2344316A1 (en) 1998-09-16 2000-03-23 Saira Sayed Singh Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
GB2344287A (en) * 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
JP2003503367A (ja) 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
PT1216043E (pt) * 1999-10-01 2003-09-30 Degussa Forma de libertacao retardada contendo (derivados de) acido alfa-lipoico
DE19949897A1 (de) * 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
EA008449B1 (ru) * 1999-12-08 2007-06-29 Фармация Корпорейшн Кристаллическая форма эплеренона
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
CN1183965C (zh) 2000-02-04 2005-01-12 尤尼金实验室公司 鼻内降钙素制剂
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
WO2001089477A2 (en) * 2000-05-19 2001-11-29 Battelle Memorial Institute Controlled release of materials from polymer matrices
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
DE10036051A1 (de) * 2000-07-25 2002-02-07 Beiersdorf Ag Kosmetische oder dermatologische Formulierungen zur Pflege und Kühlung der Haut nach einem Sonnenbad
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
ES2250502T3 (es) * 2000-12-13 2006-04-16 Merckle Gmbh Microparticulas con un perfil de liberacion mejorado y procedimient0 para su preparacion.
JP2004516262A (ja) 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
WO2002053136A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
JP5160005B2 (ja) * 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
BR0212985A (pt) * 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
US6872725B2 (en) * 2001-09-25 2005-03-29 Pharmacia Corporation Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole
NZ532198A (en) * 2001-10-18 2006-03-31 Samyang Corp Polymeric micelle composition of an amphiphilic block copolymer and a polylactic acid derivative
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
AU2003221497A1 (en) * 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
WO2003077891A1 (fr) * 2002-03-18 2003-09-25 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicales en poudre pour inhalation et procede de production de celles-ci
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7060299B2 (en) * 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CN102552917A (zh) * 2003-08-13 2012-07-11 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
KR101121403B1 (ko) * 2003-09-08 2012-04-12 추가이 세이야쿠 가부시키가이샤 히알루론산 수식물, 및 그것을 사용한 약물 담체
US7901707B2 (en) * 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
JP2005270891A (ja) * 2004-03-26 2005-10-06 Tetsuo Kondo 多糖類の湿式粉砕方法
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
WO2005110369A2 (en) * 2004-04-30 2005-11-24 American Pharmaceutical Partners, Inc. Sustained-release microspheres and methods of making and using same
JP2007537288A (ja) * 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
EP2335689A1 (en) * 2004-05-12 2011-06-22 Baxter International Inc. Method of manufacturing nucleic acid micropheres
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP3424950A1 (en) 2006-10-06 2019-01-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US7910135B2 (en) * 2006-10-13 2011-03-22 Uluru Inc. Hydrogel wound dressing and biomaterials formed in situ and their uses
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20080228268A1 (en) * 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
BRPI0705072B8 (pt) * 2007-04-27 2021-05-25 Univ Estadual Campinas Unicamp grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
JP2010533157A (ja) 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド ヒト膵臓ポリペプチド（ｈｐｐ）類似体および摂食行動に対するそれらの影響
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CN102665683A (zh) * 2009-10-12 2012-09-12 丽卡实验有限公司 紧急避孕药
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
AU2012214137B2 (en) * 2011-02-11 2016-10-06 Edge Therapeutics, Inc. Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
CN103842343B (zh) 2011-07-22 2016-08-31 坎莫森特里克斯公司 4-叔丁基-n-[4-氯-2-(1-氧基-吡啶-4-羰基)-苯基]-苯磺酰胺的钠盐的晶形
EP2734204A4 (en) 2011-07-22 2015-03-18 Chemocentryx Inc POLYMORPHIC FORMS OF 4-TERT-BUTYL-N- [4-CHLORO-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZENE-SULFONAMIDE SODIUM SALT
EA027972B1 (ru) 2011-09-01 2017-09-29 Глэксо Груп Лимитед Новая кристаллическая форма
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
EP3536318A1 (en) 2013-07-02 2019-09-11 Cortice Biosciences, Inc. Treatment of neurodegenerative disorders
WO2015143310A1 (en) 2014-03-21 2015-09-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
KR20230165365A (ko) 2014-04-15 2023-12-05 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US10383900B2 (en) * 2014-05-22 2019-08-20 Aobiome Llc Systems and methods for storage and delivery of ammonia oxidizing bacteria
CA2949833C (en) 2014-05-22 2024-06-11 Aobiome Llc Methods of preparing materials with ammonia oxidizing bacteria and testing materials for ammonia oxidizing bacteria
WO2015177572A1 (en) 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
GB201410507D0 (en) 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
AU2015278728B2 (en) 2014-06-25 2018-01-18 Glaxosmithkline Intellectual Property Development Limited Crystalline salts of (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
US20170283404A1 (en) 2014-09-08 2017-10-05 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016164412A1 (en) 2015-04-07 2016-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hypoxia-inducible factor 1 (hif-1) inhibitors
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
SG10201913934WA (en) 2015-07-02 2020-03-30 Aobiome Llc Microbiome-compatible cosmetics
KR102769297B1 (ko) 2015-07-02 2025-02-19 에이오바이오미 엘엘씨 좌창의 치료를 위한 암모니아 산화 박테리아
ES3014543T3 (en) 2016-03-02 2025-04-23 Univ Pittsburgh Commonwealth Sys Higher Education Matrix bound nanovesicles and their use
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3487513A1 (en) 2016-07-19 2019-05-29 Aobiome LLC Ammonia oxidizing microorganisms for use and delivery to the gastrointestinal system
EP3515464B1 (en) 2016-09-21 2025-11-05 Aobiome LLC Ammonia oxidizing microorganisms for use and delivery to the intranasal system
RU2649743C1 (ru) * 2016-10-24 2018-04-04 Станислав Анатольевич Кедик Жидкая лекарственная форма, содержащая лекарственное вещество, помещенное в биоразлагаемые полимеры
WO2018111888A1 (en) 2016-12-12 2018-06-21 Aobiome Llc Ammonia oxidizing microorganisms for the regulation of blood pressure
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN110352064B (zh) 2017-03-02 2023-11-10 联邦高等教育系统匹兹堡大学 用于癌症治疗的胞外基质(ecm)水凝胶及其可溶级分
US20200206277A1 (en) 2017-06-13 2020-07-02 Aobiome Llc Ammonia oxidizing microorganisms for dispersing biofilms
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
CN108159002B (zh) * 2018-01-09 2020-06-16 大连理工大学 一种洋葱仿生多层结构可控释药载体的制备方法
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
GB201908426D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
EP3750524A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Delayed and sustained delivery of anticancer drugs
EP4031108B1 (de) * 2019-09-19 2025-04-02 AMW GmbH Extrudierte depotform mit kontrollierter wirkstofffreisetzung
GB202009007D0 (en) 2020-06-12 2020-07-29 Univ Bath Modulators of tight junction permeability
GB2616205A (en) 2020-12-11 2023-08-30 Ip2Ipo Innovations Ltd Novel compounds
CN113398089A (zh) * 2021-06-29 2021-09-17 海南通用三洋药业有限公司 一种尼麦角林胶囊的制备方法和尼麦角林胶囊
JP7735140B2 (ja) * 2021-09-28 2025-09-08 株式会社ナリス化粧品 乳化組成物
CN115068435B (zh) * 2022-08-03 2023-04-25 昆山龙灯瑞迪制药有限公司 一种尼麦角林片的制备方法
GB202217575D0 (en) 2022-11-24 2023-01-11 Imperial College Innovations Ltd Novel compounds
GB202302686D0 (en) 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
WO2025085868A2 (en) 2023-10-20 2025-04-24 Radiation Control Technologies, Inc. Cd47-targeting morpholinos
GB202401189D0 (en) 2024-01-30 2024-03-13 Univ Bath Anti-viral agents
WO2025176999A2 (en) 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3916020C2 (de) * 1989-05-17 1994-06-01 Burkhard Dr Wichert Retardierende Mikropartikel aus bioabbaubaren Polyestern; Verfahren zu deren Herstellung unter Verzicht auf toxische Lösungsmittel und diese Mikropartikel enthaltende pharmazentische Zubereitungen

Also Published As

Publication number Publication date
ATE141788T1 (de) 1996-09-15
JPH04283510A (ja) 1992-10-08
IT9022155A0 (it) 1990-11-22
DE69121675T2 (de) 1997-03-06
IT9022155A1 (it) 1992-05-23
EP0486959A1 (en) 1992-05-27
US5536508A (en) 1996-07-16
US5700486A (en) 1997-12-23
JP3293862B2 (ja) 2002-06-17
DE69121675D1 (de) 1996-10-02
ES2094781T3 (es) 1997-02-01
EP0486959B1 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
IT1243390B (it) Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2296374A1 (en) Semi-interpenetrating polymer networks
CA2430481A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
NO20012395D0 (no) Fremgangsmåter for å fremstille belagte legemiddelpartikler og farmasöytiske formuleringer derav
DE69133324D1 (de) Pharmazeutische Zusammensetzungen mit kontinuierlicher Abgabe, die mit wasserlöslichen Polymeren kovalent gebundene Polypeptide enthalten
YU31599A (sh) Brzo oslobadjajući i za ukus maskirajući farmaceutski oblik doze
ATE95983T1 (de) Graduelle verabreichungsstrukturen fuer kaugummi.
Shalaby et al. Polymers of biological and biomedical significance
ATE230978T1 (de) Verfahren und zubereitungen zum verbessern der bioadhäsiv-eigenschaften von polymeren unter verwendung organischer excipienten
DK1125577T3 (da) Væskeformige medikamentindföringspræparater
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
EE9800383A (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks, mikroosakesed ja nendest koosnev materjal, farmatseutiline kompositsioon ning mikroosakeste kasutamine
NO20000913L (no) Sfæriske mikropartikler inneholdende lineære polysakkarider
PT907356E (pt) Particulas aerodinamicamente leves para administracao pulmonar de farmacos
FI972963A7 (fi) Biohajoavia polymeerejä, menetelmiä niiden valmistamiseksi ja niiden käyttö biohajoavien muovaustuotteiden valmistamiseen
ATE285754T1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
PT1195160E (pt) Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
CA2324254A1 (en) Sustained-release composition including amorphous polymer
SE9403905D0 (sv) New formulations
WO2004096155A3 (en) Tablets and methods for modified release of hydrophilic and other active agents
DK1484033T3 (da) Flydende polymersammensætninger til kontrolleret frigivelse af bioaktive stoffer
GB2317340A (en) Polymeric lamellar substrate particles for drug delivery

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19961127